Department of Vascular and Endovascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany.
Langenbecks Arch Surg. 2009 Nov;394(6):1101-7. doi: 10.1007/s00423-009-0468-x. Epub 2009 Mar 3.
To analyze early and midterm results after open and endovascular treatment of traumatic aortic transections (TAT).
Between January 1990 and December 2007, a total of 28 patients were treated for TAT due to blunt deceleration trauma. Open repair (Group 1: OR) was performed in 14 patients (50%) and thoracic endovascular aortic repair (Group 2: TEVAR) in 14 (50%). A retrospective analysis of these patients was performed. For risk stratification, the Injury Severity Score (ISS), the Glascow Coma Scale, the Revised Trauma Score, and the Trauma Injury Severity Score were used. Mean follow-up was 52.0 months (range 0.1-187.2 months)
There was no difference regarding age and hemodynamic status in either group. Risk stratification with ISS was equal in either group (OR: median 50, range 22-66 versus TEVAR: median 45, range 29-75; p = 0.354). The in-hospital mortality was 25%, with no statistical difference in either group (OR: 35.7% versus TEVAR 14.2%; p = 0.117). Procedure-related complications occurred in one patient in the OR group (bleeding) and in one patient in the TEVAR group (limb ischemia). There was no procedure-associated neurological complication in either group. One patient showed a proximal type I endoleak which is under surveillance. Early conversion due to stent graft infection was necessary in one patient. The actuarial survival estimates were 82% at 1 year and 72.5% at 3 and 5 years, with no statistical difference in both groups (p = 0.077).
Endovascular treatment of acute aortic transections is associated with a reduced perioperative mortality compared to conventional surgery with no difference regarding midterm survival. Long-term data are still required to define the definite role of TEVAR in TAT.
分析外伤性主动脉横断(TAT)开放和血管内治疗的早期和中期结果。
1990 年 1 月至 2007 年 12 月期间,共有 28 例因钝性减速伤导致 TAT 的患者接受治疗。14 例患者(50%)行开放修复(1 组:OR),14 例(50%)行胸主动脉腔内修复术(2 组:TEVAR)。对这些患者进行回顾性分析。为了风险分层,使用损伤严重程度评分(ISS)、格拉斯哥昏迷评分、修订创伤评分和创伤损伤严重程度评分。平均随访时间为 52.0 个月(0.1-187.2 个月)。
两组患者的年龄和血流动力学状态无差异。两组 ISS 风险分层相同(OR:中位数 50,范围 22-66 与 TEVAR:中位数 45,范围 29-75;p = 0.354)。院内死亡率为 25%,两组无统计学差异(OR:35.7%与 TEVAR 14.2%;p = 0.117)。OR 组有 1 例患者(出血)和 TEVAR 组有 1 例患者(肢体缺血)发生与手术相关的并发症。两组均无手术相关神经并发症。1 例患者出现近端 I 型内漏,正在监测中。1 例患者因支架移植物感染需要早期转换。1 年、3 年和 5 年的生存估计分别为 82%、72.5%,两组无统计学差异(p = 0.077)。
与传统手术相比,血管内治疗急性主动脉横断的围手术期死亡率降低,而中期生存率无差异。仍需要长期数据来确定 TEVAR 在 TAT 中的明确作用。